Skip to main content
SpringerLink
Log in

Telmisartan

A Review of its Use in Cardiovascular Disease Prevention

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Telmisartan (Micardis®, Pritor®), a well established angiotensin type 1 receptor antagonist, is indicated in the EU for the reduction of cardiovascular morbidity in patients with manifest atherothrombotic cardiovascular disease (CVD) or type 2 diabetes mellitus with documented target organ damage, as well as for the treatment of hypertension.

In the pivotal ONTARGET trial, which enrolled ACE inhibitor-tolerant patients at high vascular risk, telmisartan 80 mg once daily added to existing, proven therapy was noninferior to ramipril 10 mg once daily (the gold standard cardioprotective ACE inhibitor) in terms of CVD prevention. Moreover, telmisartan was better tolerated than ramipril, as reflected in, for example, lower incidences of permanent treatment discontinuations due to cough and angioedema. The placebo-controlled TRANSCEND and PRoFESS studies provided supporting evidence for the (time-dependent) effectiveness of telmisartan in preventing cardiovascular events, although the drug appeared to have neither a beneficial nor a harmful impact on cardiovascular mortality. The TRANSCEND trial also demonstrated that telmisartan was well tolerated in ACE inhibitor-intolerant patients at high vascular risk.

On the basis of these findings, telmisartan can be considered an effective treatment option for CVD prevention in patients at high vascular risk. Consideration may be given to prescribing the drug as an alternative to ramipril in patients who are able to tolerate ACE inhibitors and, potentially, instead of ramipril in patients who are unable to tolerate ACE inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI
Fig. 1
Table VII
Table VIII

Similar content being viewed by others

References

  1. Dahlof B. Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol 2010; 105 Suppl.: 3–9A

    Article  Google Scholar 

  2. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991 Apr; 121(4 pt 1): 1244–63

    Article  PubMed  CAS  Google Scholar 

  3. Werner C, Poss J, Bohm M. Optimal antagonism of the renin-angiotensin-aldosterone system: do we need dual or triple therapy? Drugs 2010 Jul 9; 70(10): 1215–30

    Article  PubMed  CAS  Google Scholar 

  4. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292: C82–97

    Article  PubMed  CAS  Google Scholar 

  5. Probstfield JL, O’Brien KD. Progression of cardiovascular damage: the role of renin-angiotensin system blockade. Am J Cardiol 2010; 105 Suppl.: 10–20A

    Article  CAS  Google Scholar 

  6. Hoogwerf BJ. Renin-angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol 2010; 105 Suppl.: 30–5A

    Article  CAS  Google Scholar 

  7. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61(10): 1501–29

    Article  PubMed  CAS  Google Scholar 

  8. Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs 2006; 66(1): 51–83

    Article  PubMed  CAS  Google Scholar 

  9. Deppe S, Boger RH, Weiss J, et al. Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert Opin Drug Metab Toxicol 2010 Jul; 6(7): 863–71

    Article  PubMed  CAS  Google Scholar 

  10. Micardis 20 mg, 40 mg and 80 mg tablets: summary of product characteristics. Bracknell, UK: Boehringer Ingelheim Limited, 2009

  11. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006; 20: 953–70

    Article  PubMed  CAS  Google Scholar 

  12. Wienen W, Entzeeroth M, van Meel JCA, et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev 2000; 18: 127–56

    Article  CAS  Google Scholar 

  13. Kakuta H, Sudoh K, Sasamata M, et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25(1): 41–6

    PubMed  CAS  Google Scholar 

  14. Maillard MP, Perregaux C, Centeno C, et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharm Exp Ther 2002; 302(3): 1089–95

    Article  CAS  Google Scholar 

  15. Burnier M. Telmisartan:a different angiotensin II receptor blocker protecting a different population? J Int Med Res 2009; 37: 1662–79

    PubMed  CAS  Google Scholar 

  16. Bichu P, Nistala R, Khan A, et al. Angiotensin receptor blockers for the reduction of proteinuria in diabetic Drugs 2011; 71 (6) patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag 2009; 5: 129–40

    PubMed  CAS  Google Scholar 

  17. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARg-modulating activity. Hypertension 2004 May; 43(5): 993–1002

    Article  PubMed  CAS  Google Scholar 

  18. Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor-γ modulators with angiotensin receptor blocking activity. Diabetes 2005 Dec; 54(12): 3442–52

    Article  PubMed  CAS  Google Scholar 

  19. Symeonides P, Koulouris S, Triantafyllou K, et al. Favourable pleiotropic effects of ramipril and telmisartan on vascular endothelium of diabetic patients [abstract no. 1155-111]. J Am Coll Cardiol 2005; 45 Suppl. A: 428A

    Google Scholar 

  20. Mattioli AV, Lattanzi A, Bonatti S, et al. Left atrial volume in hypertension: effect of chronic treatment with a AT2 blocker [abstract no. P3635 plus poster]. Presented at the 27th Annual Meeting of the European Society of Cardiology; 2005 Sep 3; Stockholm. Eur Heart J 2005; 26: 614

    Google Scholar 

  21. Nakayama S, Watada H, Mita T, et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type 2 diabetics with hypertension. Hypertens Res 2008; 31: 7–13

    Article  PubMed  CAS  Google Scholar 

  22. Koulouris S, Symeonides P, Triantafyllou K, et al. Comparisono of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidised low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Am J Cardiol 2005; 95(11): 1386–8

    Article  PubMed  CAS  Google Scholar 

  23. Yano Y, Hoshide S, Ishikawa J, et al. The differential effects of angiotensin II type 1 receptor blockers on micro-albuminuria in relation to low-grade inflammation in metabolic hypertensive patients. Am J Hypertens 2007; 20: 565–72

    Article  PubMed  CAS  Google Scholar 

  24. Tomiyama H, Yamada J, Koji Y, et al. Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels. Am J Hypertens 2007 Dec; 20(12): 1305–11

    Article  PubMed  CAS  Google Scholar 

  25. Schmieder RE, Delles C, Mimran A, et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007 Jun; 30(6): 1351–6

    Article  PubMed  CAS  Google Scholar 

  26. Wago T, Yoshimoto T, Akasa I, et al. Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan. Hypertens Res 2010; 33(8): 796–801

    Article  PubMed  CAS  Google Scholar 

  27. Asmar R, Gosse P, Topouchian J, et al. Effects of telmisartan on arterial stiffness in type 2 diabetes patients with essential hypertension. J Renin Angiotensin Aldosterone Syst 2002 Sep; 3(3): 176–80

    Article  PubMed  CAS  Google Scholar 

  28. Kinouchi K, Ichihara A, Sakoda M, et al. Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients. Kidney Blood Press Res 2010; 33(4): 304–12

    Article  PubMed  CAS  Google Scholar 

  29. Negro R, Hassan H. The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients. J Renin Angiotensin Aldosterone Syst 2006 Dec; 7(4): 243–6

    Article  PubMed  CAS  Google Scholar 

  30. Benndorf RA, Rudolph T, Appel D, et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 2006 Sep; 55(9): 1159–64

    Article  PubMed  CAS  Google Scholar 

  31. Negro R, Formoso G, Hassan H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest 2006 Dec; 29(11): 957–61

    PubMed  CAS  Google Scholar 

  32. Derosa G, Fogari E, D’Angelo A, et al. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007 Jun; 32(3): 261–8

    Article  PubMed  CAS  Google Scholar 

  33. Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 2007; 25: 841–8

    Article  PubMed  CAS  Google Scholar 

  34. Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005 May 15; 4: 6

    Article  PubMed  CAS  Google Scholar 

  35. Ichikawa Y. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med 2007; 46: 1331–6

    Article  PubMed  Google Scholar 

  36. Watanabe M, Inukai K, Sumita T, et al. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. Intern Med 2010; 49(17): 1843–7

    Article  PubMed  CAS  Google Scholar 

  37. Bahadir O, Uzunlulu M, Oguz A, et al. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertens Res 2007 Jan; 30(1): 49–53

    Article  PubMed  CAS  Google Scholar 

  38. Muñoz-Torrero JFS, Rivas MD, Costo A, et al. Telmisartan improves insulin resistance in patients with low cytokine levels. J Invest Med 2011 Mar; 59(3): 602–5

    Google Scholar 

  39. Derosa G, Cicero AF, Bertone G, et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin Ther 2004 Aug; 26(8): 1228–36

    Article  PubMed  CAS  Google Scholar 

  40. Derosa G, Ragonesi PD, Mugellini A, et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, doubleblind, placebo-controlled 12-month study. Hypertens Res 2004 Jul; 27(7): 457–64

    Article  PubMed  CAS  Google Scholar 

  41. Miura Y, Yamamoto M, Tsunekawa S, et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and anti-atherogenic consequences. Diabetes Care 2005; 28: 757–8

    Article  PubMed  Google Scholar 

  42. Aoki A, Ogawa T, Sumino H, et al. Long-term effects of telmisartan on blood pressure, the renin-angiotensin-aldosterone system, and lipids in hypertensive patients. Heart Vessels 2010; 25(3): 195–202

    Article  PubMed  Google Scholar 

  43. Mattioli AV, Zennaro M, Bonatti S, et al. Regression of left ventricular hypertrophy and improvement in diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol 2004 Dec; 97(3): 383–8

    Article  PubMed  CAS  Google Scholar 

  44. Mattioli AV, Bonatti S, Monopoli D, et al. Influence of regression of left ventricular hypertrophy on left atrial size and function in patients with moderate hypertension. Blood Press 2005; 14: 273–8

    Article  PubMed  Google Scholar 

  45. Galzerano D, Tammaro P, Cerciello A, et al. Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study. J Hum Hypertens 2004 Jan; 18(1): 53–9

    Article  PubMed  CAS  Google Scholar 

  46. Conrady AO, Kiselev IO, Usachev NI, et al. Effect of 24-week treatment with telmisartan on myocardial structure and function: relationship to insertion/deletion polymorphism of the angiotensin-converting enzyme gene. J Int Med Res 2005; 33 Suppl. 1: 30–8A

    Google Scholar 

  47. Petrovic J, Petrovic D, Vukovic N. Ventricular and vascular remodelling: effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res 2005; 33 Suppl. 1: 39–49A

    Google Scholar 

  48. Ivanova OV, Fomicheva OA, Segakova LM, et al. Angiotensin II receptor blocker telmisartan: effect on blood pressure profile and left ventricular hypertrophy in patients with arterial hypertension. J Int Med Res 2005; 33 Suppl. 1: 21–9A

    Google Scholar 

  49. Martina B, Dieterle T, Sigle JP, et al. Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension: a randomized, double-blind trial [letter]. Cardiology 2003; 99(3): 169–70

    Article  PubMed  Google Scholar 

  50. Galzerano D, Tammaro P, del Viscovo L, et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens 2005 Dec; 18(12Pt 1): 1563–9

    Article  PubMed  CAS  Google Scholar 

  51. Fountoulaki K, Dimopoulos V, Giannakoulis J, et al. Left ventricular mass and mechanics in mild-to-moderate hypertension: effect of nebivolol versus telmisartan. Am J Hypertens 2005; 18(2): 171–8

    Article  PubMed  CAS  Google Scholar 

  52. Galzerano D, Caselli S, Breglio R, et al. A multicentre, randomized study comparing efficacy of telmisartan versus carvedilol in preventing atrial fibrillation recurrence in hypotensive patients. Circulation 2007; 116 Suppl. II: 556–7

    Google Scholar 

  53. Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007 Jun; 30(6): 1577–8

    Article  PubMed  CAS  Google Scholar 

  54. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004 Nov 4; 351(19): 1952–61

    Article  PubMed  CAS  Google Scholar 

  55. Bakris G, Burgess E, Weir M, et al. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008 Aug; 74(3): 364–9

    Article  PubMed  CAS  Google Scholar 

  56. Galle J, Schwedhelm E, Pinnetti S, et al. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2008 Oct; 23(10): 3174–83

    Article  PubMed  CAS  Google Scholar 

  57. Redón J, Luque-Otero M, Martell N, et al. Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J 2005; 5: 14–20

    Article  PubMed  CAS  Google Scholar 

  58. Takai S, Kirimura K, Jin D, et al. Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 2005; 28: 593–600

    Article  PubMed  CAS  Google Scholar 

  59. Takaya T, Kawashima S, Shinohara M, et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis 2006; 186: 402–10

    Article  PubMed  CAS  Google Scholar 

  60. Amano S, Yamagishi S, Inagaki Y, et al. Angiotensin II stimulates platelet-derived growth factor-B gene expression in cultured retinal pericytes through intracellular reactive oxygen species generation. Tissue React 2003; 25: 51–5

    CAS  Google Scholar 

  61. Yamagishi S, Amano S, Inagaki Y, et al. Angiotensin II type 1 receptor interaction upregulates vascular endothelial growth factor messanger RNA levels in retinal pericytes through intracellular reactive oxygen species generation. Drugs Exp Clin Res 2003; 29: 75–80

    PubMed  CAS  Google Scholar 

  62. Nagai N, Izumi-Nagai K, Oike Y, et al. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kB pathway. Invest Opthalmol Vis Sci 2007; 48: 4342–50

    Article  Google Scholar 

  63. Usui T, Sugisaki K, Iriyama A, et al. Inhibition of corneal neovascularization by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 2008; 49: 4370–6

    Article  PubMed  Google Scholar 

  64. Dai Q, Xu M, Yao M, et al. Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br J Pharmacol 2007; 152: 1042–8

    Article  PubMed  CAS  Google Scholar 

  65. Blessing E, Preusch M, Kranzhofer R, et al. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. Atherosclerosis 2008; 199: 295–303

    Article  PubMed  CAS  Google Scholar 

  66. Nakamura K, Yamagishi S, Nakamura Y, et al. Telmisartan inhibits expression of a receptor for advanced glycation endproducts (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 2005; 70: 137–41

    Article  PubMed  CAS  Google Scholar 

  67. Galzerano D, Capogrosso C, Di Michele S, et al. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag 2010; 6: 113–33

    Article  PubMed  CAS  Google Scholar 

  68. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358(15): 1547–59

    Article  PubMed  CAS  Google Scholar 

  69. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372(9638): 547–53

    Article  PubMed  CAS  Google Scholar 

  70. The telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial [published erratum appears in Lancet 2008 Oct 18; 372 (9647): 1384]. Lancet 2008; 372(9644): 1174–83

    Article  CAS  Google Scholar 

  71. Mann JF, Schmieder RE, Dyal L, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009 Jul 7; 151(1): 1–10, W1-2

    PubMed  Google Scholar 

  72. Xu J, Culman J, Blume A, et al. Treatment with telmisartan and lithium of stroke-prone spontaneously hypertensive rats: survival study. Naunyn Schmiedbergs Arch Pharmacol 2002; 365 Suppl. 1: R67

    Article  CAS  Google Scholar 

  73. Dupuis F, Atkinson J, Limiñana P, et al. Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive rats. J Hypertens 2005 May; 23(5): 1061–6

    Article  PubMed  CAS  Google Scholar 

  74. Dupuis F, Vincent JM, Liminana P, et al. Effects of sub-optimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat. J Hypertens 2010 Jul; 28(7): 1566–73

    Article  PubMed  CAS  Google Scholar 

  75. Yusuf S, Diener H-C, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359(12): 1225–37

    Article  PubMed  CAS  Google Scholar 

  76. Barreras A, Gurk-Turner C. Angiotensin II receptor blockers. Proc (Bayl Univ Med Cont) 2003; 16: 123–6

    Google Scholar 

  77. Teo KK. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148(1): 52–61

    Article  PubMed  CAS  Google Scholar 

  78. Boehringer Ingelheim Pharmaceuticals. Effectiveness and safety of ramipril alone compared with telmisartan alone and in combination with ramipril in patients at high risk for cardiovascular events. Patients intolerant to ramipril were entered in TRANSCEND, Telmisartan compared to placebo [ClinicalTrials.gov identifier NCT00153101]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Sep 22

  79. Verdecchia P, Sleight P, Mancia G, et al. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation 2009 Oct 6; 120(14): 1380–9

    Article  PubMed  CAS  Google Scholar 

  80. Diener H-C, Sacco R, Yusuf S, et al. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: The Prevention Regimen for Effectively Avoiding Second Strokes trial (PRoFESS) [published erratum appears in Cerebrovasc Dis 2008; 25 (1–2): 192]. Cerebrovasc Dis 2007; 23(5–6): 368–80

    Article  PubMed  CAS  Google Scholar 

  81. Boehringer Ingelheim Pharmaceuticals. PRoFESS: prevention regimen for effectively avoiding second strokes [Clinical-Trials.gov identifier NCT00153062]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Oct 6]

  82. Topouchian J, El Feghali R, Pannier B, et al. Arterial stiffness and pharmacological interventions: the TRanscend arterial stiffNess Substudy (TRANS study). Vasc Health Risk Manag 2007; 3(4): 381–7

    PubMed  Google Scholar 

  83. Cowan BR, Young AA, Anderson C, et al. The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics. Clin Res Cardiol 2009 Jul; 98(7): 421–33

    Article  PubMed  CAS  Google Scholar 

  84. Bohm M, Baumhakel M, Probstfield JL, et al. Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ON-going Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). Am Heart J 2007; 154(1): 94–101

    Article  PubMed  CAS  Google Scholar 

  85. Cowan BR, Young AA, Anderson C, et al. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global End-point Trial). Am J Cardiol 2009 Dec 1; 104(11): 1484–9

    Article  PubMed  CAS  Google Scholar 

  86. Bohm M, Baumhakel M, Teo K, et al. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation 2010 Mar 30; 121(12): 1439–46

    Article  PubMed  Google Scholar 

  87. Berlaimont V, Billiouw JM, Brohet C, et al. Lessons from ONTARGET. Acta Clin Belg 2008 May; 63(3): 142–51

    PubMed  CAS  Google Scholar 

  88. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 Jan 20; 342(3): 145–53

    CAS  Google Scholar 

  89. Warner GT, Perry CM. Ramipril: a review of its use in the prevention of cardiovascular outcomes. Drugs 2002; 62(9): 1381–405

    Article  PubMed  CAS  Google Scholar 

  90. Patel A; ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370(9590): 829–40

    Article  PubMed  CAS  Google Scholar 

  91. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008 Sep 18; 359(12): 1238–51

    Article  PubMed  CAS  Google Scholar 

  92. Schneck MJ. Understanding the PRoFESS study for secondary stroke prevention. Curr Treat Options Cardiovasc Med 2009 Jun; 11(3): 221–31

    Article  PubMed  Google Scholar 

  93. Algra A. Digestion of the antiplatelets comparison of Profess: 18−7=1? Stroke 2009 May; 40(5): 1932–5

    Article  PubMed  Google Scholar 

  94. European Medicines Agency. Assessment report for Pritor. International non-proprietary name/common name: telmisartan. Procedure no. EMEA/H/C/000210/II/00084. 2009 Nov 23

  95. Kurtz TW, Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res 2009 Oct; 32(10): 826–34

    Article  PubMed  CAS  Google Scholar 

  96. Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press 2008; 17 Suppl. 1: 32–40

    Article  CAS  Google Scholar 

  97. Michel MC, Bohner H, Köster J, et al. Safety of telmisartan in patients with arterial hypertension: an open-label observational study. Drug Saf 2004; 27(5): 335–44

    Article  PubMed  CAS  Google Scholar 

  98. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28: 2375–414

    PubMed  Google Scholar 

  99. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 Suppl. V: v1–52

    Article  Google Scholar 

  100. Weber MA, Messerli FH. Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. Hypertension 2008; 51: 1465–7

    Article  PubMed  CAS  Google Scholar 

  101. Dykewicz MS. Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management. Curr Opin Allergy Clin Immunol 2004 Aug; 4(4): 267–70

    Article  PubMed  CAS  Google Scholar 

  102. Elliot HL. Focus on the ONTARGET results. J Hypertens Suppl. 2009 Jun; 27(2): S8–10

    Article  CAS  Google Scholar 

  103. Volpe M. A new option for therapeutic management of patients with cardiovascular disease: a closer look at the ONTARGET study. High Blood Press Cardiovasc Prev 2008; 15(2): 47–51

    Article  Google Scholar 

  104. Diener HC. Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs. J Hypertens Suppl. 2009 Jul;27(5):S31–6

    Article  PubMed  CAS  Google Scholar 

  105. Teo KK. Clinical evidence from ONTARGET: proven cardio- and vascular protection. Eur Heart J 2009; 11 Suppl. F: F9–15

    Article  CAS  Google Scholar 

  106. Bohm M, Baumhakel M, Mahfoud F, et al. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors. Cardiology 2010 Nov 4; 117(3): 163–73

    Article  PubMed  CAS  Google Scholar 

  107. Liebson PR, Amsterdam EA. Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk. Prev Cardiol 2009; 12: 43–50

    Article  PubMed  Google Scholar 

  108. Fitchett D. Results of the ONTARGET and TRANSCEND studies: an update and discussion. Vasc Health Risk Manag 2009; 5(1): 21–9

    PubMed  CAS  Google Scholar 

  109. Jugdutt BI. Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. Clin Interv Aging 2010; 5: 403–16

    Article  PubMed  CAS  Google Scholar 

  110. Kintscher U. ONTARGET, TRANSCEND, and PRoFESS: new-onset diabetes, atrial fibrillation, and left ventricular hypertrophy. J Hypertens Suppl. 2009 Jun; 27(2): S36–9

    Article  PubMed  CAS  Google Scholar 

  111. Ramipril 10mg capsules: summary of product characteristics. Guilford, UK: Winthrop Pharmaceuticals UK Ltd., 2009 Nov 11

  112. Micardis (telmisartan) tablets: US prescribing information. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc., 2009 Nov

  113. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003 Nov 13; 349(20): 1893–906

    Article  PubMed  CAS  Google Scholar 

  114. Rizos CV, Elisaf MS, Liberopoulos EN. Are the pleiotropic effects of telmisartan clinically relevant. Curr Pharm Des 2009; 15(24): 2815–32

    Article  PubMed  CAS  Google Scholar 

  115. Fitchett D. Clinical trial update: focus on the ONTARGET study. Vasc Health Risk Manag 2007; 3(6): 901–8

    PubMed  Google Scholar 

  116. Tobe SW, Clase CM, Gao P, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011; 123: 1098–107

    Article  PubMed  CAS  Google Scholar 

  117. Heerspink HJL, de Zeeuw D. ONTARGET still OFF-TARGET? Circulation 2011; 123: 1049–51

    Article  Google Scholar 

  118. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic failure. N Engl J Med 2001; 345: 1667–75

    Article  PubMed  CAS  Google Scholar 

  119. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet 2003 Sep 6; 362(9386): 767–71

    Article  PubMed  CAS  Google Scholar 

  120. Bangalore S, Kumar S, Kjeldsen SE, et al. Anti-hypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011 Jan; 12(1): 65–82

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    James E. Frampton

Authors
  1. James E. Frampton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James E. Frampton.

Additional information

Various sections of the manuscript reviewed by: M. Burnier, Division of Nephrology and Hypertension Consultation, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; M.S. Elisaf, Department of Internal Medicine, University of Ioannina Medical School, Ioannina, Greece; A. Oguz, Department of Internal Medicine, Goztepe Training and Research Hospital, Istanbul, Turkey; W. Van Mieghem, Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; P. Verdecchia, Department of Cardiology, Clinical Research Unit ‘Preventive Cardiology’, Hospital Santa Maria della Misericordia, Perugia, Italy; M. Volpe, Division of Cardiology, Department of Clinical and Molecular Medicine, 2nd Faculty of Medicine, Sapienza University, Rome, Italy.

Data Selection

Sources: Medical literature published in any language since 1980 on ‘telmisartan’, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: MEDLINE search terms were ‘telmisartan’ or ‘BIBR-277’ and (‘hypertension’ or ‘hypertensive’). EMBASE search terms were ‘telmisartan’ and (‘hypertension’ or ‘hypertensive’). AdisBase search terms were ‘telmisartan’ or BIBR-277’ and (‘hypertension’ or ‘hypertensive’). Searches were last updated 5 March 2011.

Selection: Studies in patients with manifest atherothrombotic cardiovascular disease or type 2 diabetes mellitus who received telmisartan. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Telmisartan, angiotension type 1 receptor antagonist, cardiovascular disease prevention, cardiovascular morbidity and mortality, pharmacodynamics, pharmacokinetics, therapeutic use, tolerability.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frampton, J.E. Telmisartan. Drugs 71, 651–677 (2011). https://doi.org/10.2165/11206710-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11206710-000000000-00000

Keywords

Search

Navigation